Key result
Spray drying of Sabin inactivated polio vaccine achieved 98% and 97% recovery for serotypes 1 and 2, respectively, but serotype 3 was more challenging with only 56% recovery after drying.
Different serotypes of Sabin inactivated polio vaccine require distinct excipient formulations for optimal stability during spray drying, suggesting they should be dried separately before mixing.
Serotype-specific drying losses in Sabin IPV; leaves open whether unified excipient strategies can ensure consistent potency in multivalent formulations.
The objective of this study was to develop a stable spray dried formulation, containing the three serotypes of Sabin inactivated polio vaccine (sIPV), aiming for minimal loss of native conformation (D-antigen) during drying and subsequent storage. The influence of atomization and drying stress during spray drying on trivalent sIPV was investigated. This was followed by excipient screening, in which monovalent sIPV was formulated and spray dried. Excipient combinations and concentrations were tailored to maximize both the antigen recovery of respective sIPV serotypes after spray drying and storage (T = 40 °C and t = 7 days). Furthermore, a fractional factorial design was developed around the most promising formulations to elucidate the contribution of each excipient in stabilizing D-antigen during drying. Serotype 1 and 2 could be dried with 98% and 97% recovery, respectively. When subsequently stored at 40 °C for 7 days, the D-antigenicity of serotype 1 was fully retained. For serotype 2 the D-antigenicity dropped to 71%. Serotype 3 was more challenging to stabilize and a recovery of 56% was attained after drying, followed by a further loss of 37% after storage at 40 °C for 7 days. Further studies using a design of experiments approach demonstrated that trehalose/monosodium glutamate and maltodextrin/arginine combinations were crucial for stabilizing serotype 1 and 2, respectively. For sIPV serotype 3, the best formulation contained Medium199, glutathione and maltodextrin. For the trivalent vaccine it is therefore probably necessary to spray dry the different serotypes separately and mix the dry powders afterwards to obtain the trivalent vaccine.
No takes yet. Share an insight, caveat, or question.
Kanojia et al. (2018) studied Polio vaccine formulation. Spray drying and excipient formulation was evaluated on D-antigen recovery after spray drying and storage. Spray drying of Sabin inactivated polio vaccine achieved 98% and 97% recovery for serotypes 1 and 2, respectively, but serotype 3 was more challenging with only 56% recovery after drying.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: